A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
作者信息
Beksac Meral, Seval Guldane Cengiz, Kanellias Nicholas, Coriu Daniel, Rosiñol Laura, Ozet Gulsum, Goranova-Marinova Vesselina, Unal Ali, Bila Jelena, Ozsan Hayri, Ivanaj Arben, Balić Lejla Ibricevic, Kastritis Efstathios, Bladé Joan, Dimopoulos Meletios Athanasios
机构信息
Department of Hematology, School of Medicine, Ankara University, Ankara, Turkey.
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
出版信息
Haematologica. 2021 Apr 1;106(4):1228. doi: 10.3324/haematol.2020.278272.
Abstract
摘要
相似文献
1
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.巴尔干骨髓瘤研究组和巴塞罗那大学关于髓外疾病的一项真实世界多中心回顾性研究：改善预后的参数分析
Haematologica. 2021 Apr 1;106(4):1228. doi: 10.3324/haematol.2020.278272.
2
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.巴尔干骨髓瘤研究组和巴塞罗那大学的一项真实世界多中心回顾性研究：分析改善预后的参数。
Haematologica. 2020 Jan;105(1):201-208. doi: 10.3324/haematol.2019.219295. Epub 2019 Jul 5.
3
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.FDG-PET/CT 在髓外多发性骨髓瘤中的作用：FDG-PET/CT 结果与临床结局的相关性。
Clin Nucl Med. 2016 Jan;41(1):e7-13. doi: 10.1097/RLU.0000000000000902.
4
Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.动态对比增强超声在髓外骨髓瘤特征描述和监测中的作用：与血清学数据的比较。
J Ultrasound Med. 2013 Oct;32(10):1777-88. doi: 10.7863/ultra.32.10.1777.
5
Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the cat.猫骨髓瘤相关疾病的组织病理学、免疫组织化学和细胞学分析：猫原发性髓外发育的进一步证据
Vet Pathol. 2008 Mar;45(2):159-73. doi: 10.1354/vp.45-2-159.
6
[Expression of CD56 in Multiple Myeloma Cells and Its Relationship with Extramedullary Disease and Extramedullary Relapse].[CD56在多发性骨髓瘤细胞中的表达及其与髓外疾病和髓外复发的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):553-556. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.039.
7
Cytogenetics of extramedullary manifestations in multiple myeloma.多发性骨髓瘤髓外表现的细胞遗传学研究。
Br J Haematol. 2013 Apr;161(1):87-94. doi: 10.1111/bjh.12223. Epub 2013 Feb 1.
8
Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.循环血清微小RNA-130a作为髓外骨髓瘤的一种新型潜在标志物
PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015.
9
MRI features of extramedullary myeloma.髓外骨髓瘤的 MRI 特征。
AJR Am J Roentgenol. 2014 Apr;202(4):803-10. doi: 10.2214/AJR.13.10856.
10
Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.基于失调基因表达数据，多发性骨髓瘤的髓外复发被定义为最高风险组。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):288-93. doi: 10.5507/bp.2015.014. Epub 2015 Apr 16.
引用本文的文献
1
[Consensus for the diagnosis and management of extramedullary plasmacytoma in China(2024)].《中国髓外浆细胞瘤诊断与治疗专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):8-17. doi: 10.3760/cma.j.cn121090-20231107-00253.
2
Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.新诊断的伴有髓外疾病的多发性骨髓瘤患者的生存趋势和预后因素。
Ann Med. 2023;55(2):2281657. doi: 10.1080/07853890.2023.2281657. Epub 2023 Dec 12.
3
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.DCEP 联合达雷妥尤单抗治疗伴有髓外疾病的复发/难治性多发性骨髓瘤患者的 II 期临床试验。
J Hematol Oncol. 2022 Oct 23;15(1):150. doi: 10.1186/s13045-022-01374-5.
4
Extramedullary disease in multiple myeloma: a systematic literature review.多发性骨髓瘤中的髓外疾病：系统文献回顾。
Blood Cancer J. 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3.
Zotero 插件